EA201201660A1 - Очень высокая эффективность антител к cd37 в образцах крови страдающих cll пациентов - Google Patents
Очень высокая эффективность антител к cd37 в образцах крови страдающих cll пациентовInfo
- Publication number
- EA201201660A1 EA201201660A1 EA201201660A EA201201660A EA201201660A1 EA 201201660 A1 EA201201660 A1 EA 201201660A1 EA 201201660 A EA201201660 A EA 201201660A EA 201201660 A EA201201660 A EA 201201660A EA 201201660 A1 EA201201660 A1 EA 201201660A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- patients
- antibodies
- cll
- treatment
- blood samples
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
В заявке описаны антитела к CD37, прежде всего А2 и В2, предназначенные для лечения страдающих CLL пациентов, прежде всего пациентов, принадлежащих к группе "высокого риска" или "ультравысокого риска". Указанные пациенты представляют собой либо пациентов, невосприимчивых к лечению флударабином, либо пациентов, которые несут генетический маркер, свидетельствующий о плохом прогнозе или повышенном риске неблагоприятного исхода лечения, например пациентов с дисфункцией ТР53 или делецией хромосомы 17р13, либо пациентов с неблагоприятным исходом предшествующего лечения антителами к CD20. Способность А2 и В2 вызывать истощение CLL-клеток является высокой в образцах крови пациентов, взятых у пациентов из группы нормального риска и повышенного риска (пациенты "высокого риска"), и выражено превышает активность ритуксимаба и алемтузумаба.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10169795 | 2010-07-16 | ||
EP10175586 | 2010-09-07 | ||
PCT/EP2011/062133 WO2012007576A1 (en) | 2010-07-16 | 2011-07-15 | Superior efficacy of cd37 antibodies in cll blood samples |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201201660A1 true EA201201660A1 (ru) | 2013-07-30 |
EA025365B1 EA025365B1 (ru) | 2016-12-30 |
Family
ID=44546328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201201660A EA025365B1 (ru) | 2010-07-16 | 2011-07-15 | Применение антитела к cd37 для лечения пациента из группы высокого риска, страдающего хроническим лимфолейкозом (cll), способ истощения экспрессирующих cd37 в-клеток в популяции клеток с дефицитом тр53 |
Country Status (14)
Country | Link |
---|---|
US (3) | US20120189618A1 (ru) |
EP (2) | EP3252077A1 (ru) |
JP (2) | JP2013538790A (ru) |
KR (1) | KR20130100918A (ru) |
CN (2) | CN103003309A (ru) |
AU (1) | AU2011278227B2 (ru) |
BR (1) | BR112013001012A2 (ru) |
CA (1) | CA2799036A1 (ru) |
CL (1) | CL2013000101A1 (ru) |
EA (1) | EA025365B1 (ru) |
IL (1) | IL222775A (ru) |
MX (1) | MX341463B (ru) |
NZ (2) | NZ703225A (ru) |
WO (1) | WO2012007576A1 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20090499A1 (es) | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
WO2013160396A1 (en) * | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
EP2849784A1 (en) * | 2012-05-16 | 2015-03-25 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
CN114149511A (zh) * | 2015-04-13 | 2022-03-08 | 辉瑞公司 | 靶向b细胞成熟抗原的嵌合抗原受体 |
US11578115B2 (en) | 2017-01-10 | 2023-02-14 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
EP3595721A4 (en) * | 2017-03-16 | 2021-01-06 | The General Hospital Corporation | CHEMERICAL ANTIGEN RECEPTORS TARGETING CD37 |
KR20200074915A (ko) | 2017-03-31 | 2020-06-25 | 젠맵 홀딩 비.브이. | 이중특이적 항-cd37 항체, 모노클로날 항-cd37 항체 및 그의 사용 방법 |
JP7513530B2 (ja) | 2018-06-22 | 2024-07-09 | ジェンマブ ホールディング ビー.ブイ. | 抗cd37抗体および抗cd20抗体、組成物、ならびにそれらの使用方法 |
MA53812A (fr) | 2018-10-04 | 2021-08-11 | Genmab Holding B V | Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques |
WO2023057583A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 |
WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
HUE026303T2 (hu) * | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
US20080279850A1 (en) * | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
BRPI0814060A2 (pt) * | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
PE20090499A1 (es) * | 2007-08-09 | 2009-05-18 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
DK2132228T3 (da) * | 2008-04-11 | 2011-10-10 | Emergent Product Dev Seattle | CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf |
CN102271708A (zh) * | 2008-11-13 | 2011-12-07 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗联合疗法及其用途 |
-
2011
- 2011-07-14 US US13/182,471 patent/US20120189618A1/en not_active Abandoned
- 2011-07-15 NZ NZ703225A patent/NZ703225A/en not_active IP Right Cessation
- 2011-07-15 NZ NZ603161A patent/NZ603161A/en not_active IP Right Cessation
- 2011-07-15 KR KR1020127032811A patent/KR20130100918A/ko not_active Application Discontinuation
- 2011-07-15 BR BR112013001012A patent/BR112013001012A2/pt not_active IP Right Cessation
- 2011-07-15 EP EP17174088.9A patent/EP3252077A1/en not_active Withdrawn
- 2011-07-15 CN CN2011800349727A patent/CN103003309A/zh active Pending
- 2011-07-15 AU AU2011278227A patent/AU2011278227B2/en not_active Ceased
- 2011-07-15 JP JP2013519111A patent/JP2013538790A/ja active Pending
- 2011-07-15 CN CN201610095143.4A patent/CN105749276A/zh active Pending
- 2011-07-15 EA EA201201660A patent/EA025365B1/ru not_active IP Right Cessation
- 2011-07-15 WO PCT/EP2011/062133 patent/WO2012007576A1/en active Application Filing
- 2011-07-15 MX MX2012013613A patent/MX341463B/es active IP Right Grant
- 2011-07-15 EP EP11732464.0A patent/EP2593479A1/en not_active Withdrawn
- 2011-07-15 CA CA2799036A patent/CA2799036A1/en not_active Abandoned
-
2012
- 2012-10-31 IL IL222775A patent/IL222775A/en active IP Right Grant
-
2013
- 2013-01-10 CL CL2013000101A patent/CL2013000101A1/es unknown
- 2013-04-26 US US13/871,345 patent/US20130236454A1/en not_active Abandoned
-
2015
- 2015-04-13 US US14/684,928 patent/US20150266967A1/en not_active Abandoned
-
2016
- 2016-07-28 JP JP2016148217A patent/JP2017019800A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3252077A1 (en) | 2017-12-06 |
US20120189618A1 (en) | 2012-07-26 |
AU2011278227A1 (en) | 2012-11-15 |
MX341463B (es) | 2016-08-22 |
JP2017019800A (ja) | 2017-01-26 |
EP2593479A1 (en) | 2013-05-22 |
AU2011278227B2 (en) | 2017-03-02 |
CN103003309A (zh) | 2013-03-27 |
CA2799036A1 (en) | 2012-01-19 |
BR112013001012A2 (pt) | 2016-05-24 |
KR20130100918A (ko) | 2013-09-12 |
WO2012007576A1 (en) | 2012-01-19 |
NZ603161A (en) | 2015-02-27 |
IL222775A0 (en) | 2012-12-31 |
JP2013538790A (ja) | 2013-10-17 |
NZ703225A (en) | 2016-11-25 |
US20150266967A1 (en) | 2015-09-24 |
EA025365B1 (ru) | 2016-12-30 |
CL2013000101A1 (es) | 2013-12-27 |
MX2012013613A (es) | 2012-12-17 |
CN105749276A (zh) | 2016-07-13 |
US20130236454A1 (en) | 2013-09-12 |
IL222775A (en) | 2017-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201201660A1 (ru) | Очень высокая эффективность антител к cd37 в образцах крови страдающих cll пациентов | |
Kurth et al. | Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma | |
Bosiljcic et al. | Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs | |
Yung et al. | GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade | |
Fleming et al. | Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study | |
Singh et al. | Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis | |
Hao et al. | Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression | |
Liu et al. | Elevated miR-155 expression induces immunosuppression via CD39+ regulatory T-cells in sepsis patient | |
Galore-Haskel et al. | A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme | |
Sareen et al. | The role of liquid biopsies in detecting molecular tumor biomarkers in brain cancer patients | |
MX2018011480A (es) | Metodos de intervencion temprana para prevenir o aminorar toxicidad. | |
EA036698B9 (ru) | Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif | |
Chen et al. | Esophageal cancer stem cells express PLGF to increase cancer invasion through MMP9 activation | |
CN107106876A (zh) | 用于治疗免疫失调的多次‑可变il‑2剂量方案 | |
Tao et al. | Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer | |
Barnes et al. | Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients | |
Li et al. | AMD3100 inhibits brain-specific metastasis in lung cancer via suppressing the SDF-1/CXCR4 axis and protecting blood-brain barrier | |
Nakasone et al. | Therapeutic benefits targeting B-cells in chronic graft-versus-host disease | |
Liang et al. | Paeoniflorin ameliorates murine lupus nephritis by increasing CD4+ Foxp3+ Treg cells via enhancing mTNFα-TNFR2 pathway | |
He et al. | Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti–PD-1 in Metastatic Non–Small Cell Lung Cancer | |
Hussain et al. | HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy | |
Asero | Oral cyclophosphamide in a case of cyclosporin and steroid‐resistant chronic urticaria showing autoreactivity on autologous serum skin testing | |
US20190060361A1 (en) | Methods and compositions relating to regulatory t cells | |
CN109512833B (zh) | E2f6抑制剂的功能与用途 | |
Shao et al. | Combination of monoclonal antibodies with DST inhibits accelerated rejection mediated by memory T cells to induce long-lived heart allograft acceptance in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |